Citations

Clear

2960 citation(s) found for "Kim, P".

Prostate tissue ablation and drug delivery by an image-guided injectable ionic liquid in ex vivo and in vivo models
Demirlenk, Yusuf Mert , Albadawi, Hassan , Zhang, Zefu , Atar, Dila , Çevik, Enes , Keum, Hyeongseop , Kim, Jinjoo , Rehman, Suliman, Gündüz, Şeyda , Mayer, Joseph L. , Santos, Pedro Reck dos , Demirlenk, Yusuf M , Graf, Erin, Santos, Pedro Augusto Reck Dos , Oklu, Rahmi , Gunduz, Seyda , Graf, Erin H. , Öklü, Rahmi

Mayo Clinic

Science Translational Medicine | July 3, 2024 | Volume: 16 | Issue: 754 | Pages: No page available

10.1126/scitranslmed.adn7982 | PMID 38959326 Get It

Benign prostatic hyperplasia and prostate cancer are often associated with lower urinary tract symptoms, which can severely affect patient quality of life. To address this challenge, we developed and optimized an injectable compound, prostate ablation and drug delivery agent (PADA), for percutaneous prostate tissue ablation and concurrently delivered therapeutic agents. PADA is an ionic liquid composed of choline and geranic acid mixed with anticancer therapeutics and a contrast agent. The PADA formulation was optimized for mechanical properties compatible with hand injection, diffusion capability, cytotoxicity against prostate cells, and visibility of an x-ray contrast agent. PADA also exhibited antibacterial properties against highly resistant clinically isolated bacteria in vitro. Ultrasound-guided injection, dispersion of PADA in the tissue, and tissue ablation were tested ex vivo in healthy porcine, canine, and human prostates and in freshly resected human tumors. In vivo testing was conducted in a murine subcutaneous tumor model and in the canine prostate. In all models, PADA decreased the number of viable cells in the region of dispersion and supported the delivery of nivolumab throughout a portion of the tissue. In canine survival experiments, there were no adverse events and no impact on urination. The injection approach was easy to perform under ultrasound guidance and produced a localized effect with a favorable safety profile. These findings suggest that PADA is a promising therapeutic prostate ablation strategy to treat lower urinary tract symptoms.
O-111 Premature ovarian insufficiency: new data and updated guidance
Panay, Nicholas , Bennie, A, Cedars, Marcelle I. , Davies, Melanie , Kim, K., Rocca, Walter A. , Anderson, Richard A. , Bennie, Amy , Ee, Carolyn , Gravholt, Claus Højbjerg , Kalantaridou, Sophia , Kallen, Amanda Nicole , Misrahi, Micheline , Nappi, Rossella E , Ruan, Xiangyan , Teede, Helena , Vermeulen, Nathalie , Vogt, Elinor , Vincent, Amanda J

Mayo Clinic

Human Reproduction | July 3, 2024 | Volume: 39 | Issue: Supplement_1 | Pages: No page available

10.1093/humrep/deae108.122 Get It

Abstract Premature ovarian insufficiency (POI) presents a significant challenge to women's health, with significant implications both physically and emotionally. Despite its life-altering impact, there remain substantial unknowns in the causes this condition and how to optimally manage its various sequelae While such unknows provide direction for future research, they also underscore the need for clinical guidance. In 2015, under the auspices of ESHRE, a group of experts evaluated the existing best evidence and published the first European guideline on the management of premature ovarian insufficiency. The update of this Guideline was performed in an international collaboration of experts representing American Society for Reproductive Medicine (ASRM), International Menopause Society (IMS), and the Centre for Research Excellence in Women’s Health in Reproductive Life (CRE WHiRL). The recent update of the POI guideline covers 40 clinical questions on diagnosis of the condition, the different sequelae, including musculoskeletal health, cardiovascular health, neurological health, sexual function and general well being, and treatment options, including hormone therapy. The list of clinical questions was expanded from the questions included in the guideline from 2015. Based on a scoping survey and appreciation of emerging knowledge of POI, questions were added on the role of AMH in the diagnosis of POI, fertility preservation, muscle health, and specific considerations for hormone treatment in iatrogenic POI. Additionally, the topic on complementary treatments was extended with specific focus on non-hormonal treatments and lifestyle management options. The draft guideline published for stakeholder review includes a total of 142 recommendations. One third of these recommendations were formulated as good practice points. Of the evidence-based recommendations, almost 80% were formulated as strong recommendations, even if the evidence base for most evidence-based recommendations was limited to observational data (level very low or low), supporting a call for future research. The guideline group hope that the new POI Guideline will improve the clinical management of this devastating condition.
A phase 1, first-in-human study of autologous monocytes engineered to express an anti-HER2 chimeric antigen receptor (CAR) in participants with HER2-overexpressing solid tumors.
Yuan, Yuan , Krishnamurthy, Anuradha , Reiss, Kim Anna, Isaacs, James , Gabitova, Linara, Menchel, Brett, Locke, Kenneth W., WETZEL, J. M., Klichinsky, Michael , Condamine, Thomas , Sohal, Davendra , Abdou, Yara George , Pohlmann, Paula R. , Maziarz, Richard Thomas , Murthy, Hemant S. , Blumenthal, Daniel J. , Locke, Kenneth, Wetzel, Jeanette, Cushing, Daniel J.

Mayo Clinic

Journal of Clinical Oncology | July 2, 2024 | Volume: 42 | Issue: 16_suppl | Pages: TPS2682-TPS2682

10.1200/jco.2024.42.16_suppl.tps2682 Get It

TPS2682 Background: Myeloid cells are actively recruited to the solid tumor microenvironment (TME) and have the potential to mediate tumor control via phagocytosis, TME remodeling, and T cell activation. We previously developed human chimeric antigen receptor macrophages (CAR-M) and have shown potent anti-tumor activity in pre-clinical solid tumor models. The anti-HER2 CAR-M cell therapy product, CT-0508, is currently being evaluated in a Phase I trial as a monotherapy and in combination with pembrolizumab. Early clinical data have shown feasibility, safety, and validated the mechanism of action. We have developed a next-generation CAR monocyte (CAR-Mono) platform to increase the dose, improve tumor trafficking and engraftment, and shorten the manufacturing and vein-to-vein time as compared to CAR-M therapy. CT-0525 is an autologous anti-HER2 CAR-Mono cell therapy based on CD14+ monocytes engineered with an Ad5f35 adenoviral vector to express an anti-HER2 CAR. Pre-clinical studies have demonstrated the feasibility, phenotype, pharmacokinetics, durable CAR expression, cellular fate, antigen specificity, and anti-tumor activity of CT-0525. Pre-clinical studies have shown that CT-0525 differentiated into pro-inflammatory CAR-M in vivo and controlled tumor growth. The CT-0525 manufacturing process takes one day and enables the production of up to 10 billion cells from a single apheresis. CT-0525 is being investigated in a first-in-human, open-label, multi-center, Phase I study in patients with HER2 overexpressing solid tumors. Methods: This Phase 1, first-in-human study evaluates the feasibility, safety, tolerability, trafficking, TME activation, and preliminary evidence of efficacy of the investigational CAR-Mono product CT-0525 in 6 participants (pts) with locally advanced unresectable/metastatic solid tumors overexpressing HER2. Pts previously treated with anti-HER2 therapies are eligible. Filgrastim mobilized autologous CD14+ monocytes are collected by apheresis, followed by manufacturing and cryopreservation. The 1st cohort of pts (n=3) will receive 3 x 109 CT-0525 CAR positive monocytes administered IV in one infusion. If tolerated as per the modified toxicity probability interval algorithm (mTPI), the 2nd cohort of pts (n=3) will receive up to 10 x 109 CT-0525 CAR positive monocytes in one infusion. CT-0525 will be administered without conditioning chemotherapy. Primary endpoints include assessment of safety and tolerability, as well as manufacture feasibility. Correlative assessments include pre- and post-treatment biopsies and blood samples for safety, immunogenicity, pharmacokinetics, tumor trafficking, TME modulation, epitope spreading, and other translational biomarkers. Clinical trial information: NCT06254807 .
Exploring systemic treatment approaches for advanced pure large cell neuroendocrine carcinoma (LCNEC): A multicenter retrospective analysis.
Matteson, Kelsey, Ardeshir, Fatemeh, Gray, Jhanelle E. , Espinar, Javier Baena , Grohé, Christian , Pancirer, Danny, Cheung, Justin Matthew, Watson, Alexander, Kaldas, David , Kim, Chul , Awosika, Nichola, Chiang, Anne C. , Nassar, Amin H. , Kwiatkowski, David J. , Nana, Frank Aboubakar , Citarella, Fabrizio , Sridhar, Arthi , Crowley, Fionnuala , Sankar, K. Nathan , Naqash, Abdul Rafeh

Mayo Clinic

Journal of Clinical Oncology | June 28, 2024 | Volume: 42 | Issue: 16_suppl | Pages: 8106-8106

10.1200/jco.2024.42.16_suppl.8106 Get It

8106 Background: Due to lack of prospective data, the optimal first line treatment approach for patients (pts) with pure LCNEC histology remains uncertain. Methods: Across 17 centers, we conducted a retrospective analysis of metastatic pure LCNEC (diagnosed at local institutions) who received 1st-line systemic therapy between 2015-2023. Pts were either treated with chemotherapy (chemo), immunotherapy (IO), or a combination (chemoIO). Clinical outcomes were progression-free survival (PFS), overall survival (OS), objective response rates (ORR), and treatment-related adverse events (trAE) as defined using CTCAE 5.0. Survival analysis by genomic alteration status ( TP53, RB1, STK11, KEAP1, KRAS) and PD-L1 status were performed. Results: We identified 161 pts with median age of 67 years (IQR: 58-83) at 1st line systemic therapy; 54% (n = 87) were males. Median follow-up was 55 months (mo), 62 mo, and 29 mo for the chemo, IO, and chemoIO groups, respectively. 79% (n = 127) were former or current smokers. 1st-line treatments were chemo (n = 94), IO (n = 11), or chemoIO (n = 56). Of 85 pts with PD-L1 status, 58 (68%) were 0% and 27 (32%) were ≥1%. The most common chemo regimen was platinum-etoposide (n = 72, 78%). ChemoIO regimens included carboplatin/etoposide/atezolizumab (n = 23, 43%) and carboplatin/pemetrexed/pembrolizumab (n = 17, 31%). In the IO group, 1 patient received dual IO. Lung (n = 74, 46%) and liver (n = 71, 41%) were the most common sites of metastasisThere was no significant difference in PFS across the groups (median PFS [mPFS] chemoIO: 5.7 mo, 95% CI: 5.0-6.3, chemo: 5.1 mo, 95% CI: 3.1-5.9; IO: 3.6 mo, 95% CI: 1.7-6.5) on multivariable analysis adjusting for ECOG and “M” stage (p = 0.2 and 0.24 for chemoIO-chemo and chemoIO-IO comparisons, respectively). There was no difference in OS (mOS chemo: 11 mo, 95% CI: 7.6-17.4; IO: 13.6 mo, 95% CI: 5.9-not reached; chemoIO: 12.2 mo, 95% CI: 7.4-20.6, p = 0.5 and 0.8 for chemoIO-chemo and chemoIO-IO comparisons, respectively). ORR was 35.2% (31/88) in chemo, 25% (2/8) in IO, and 35.7% (20/56) in chemoIO ( p= 0.46). There were no significant differences in PFS and OS outcomes by treatment group when divided by genetic profile (n = 79, methods), or by PD-L1 status (0% vs ≥1%). Any grade trAE occurred in 48 (51%), 5 (45%), and 28 (50%) pts treated with chemo, IO, and chemoIO, respectively. Grade ≥3 toxicity profiles are shown (table). Conclusions: For 1st-line treatment of LCNEC, similar PFS, OS, and ORR were seen for chemo, IO, and chemoIO. This questions the added benefit of chemoIO compared to chemo alone, and warrants future clinical trials to discern the optimal 1st line treatment. [Table: see text]
The MAGIC algorithm probability predicts treatment response and long-term outcomes to second-line therapy for acute GVHD
DeFilipp, Zachariah , Spyrou, Nikolaos , Katsivelos, Nikolaos , Kowalyk, Steven, Eng, Gilbert, Kasikis, Stelios, Beheshti, Rahnuma, Baez, Janna , Akahoshi, Yu , Ayuk, Francis, Choe, Hannah , Etra, Aaron , Vášová, Ingrid, Young, Rachel , Holler, Ernst , Ferrara, James L.M. , Nakamura, Ryotaro , Chen, Yi‐Bin , Katsivelos, Nikolaos , Akahoshi, Yu , Hexner, Elizabeth , Hogan, William J , Qayed, Muna , Reshef, Ran , Nakamura, Ryotaro , Levine, John E , Chen, Yi-Bin , Kim, Haesook T. , Grupp, Stephan A. , Hexner, Elizabeth O. , Hogan, William J. , Kitko, Carrie L. , Reshef, Ran , Zeiser, Robert , Levine, John E.

Mayo Clinic

Blood Advances | June 28, 2024 | Volume: 8 | Issue: 13 | Pages: 3488-3496

10.1182/bloodadvances.2024012561 | PMID 38640197 Get It

Abstract The significance of biomarkers in second-line treatment for acute graft-versus-host disease (GVHD) has not been well characterized. We analyzed clinical data and serum samples at the initiation of second-line systemic treatment of acute GVHD from 167 patients from 17 centers of the Mount Sinai Acute GVHD International Consortium (MAGIC) between 2016 and 2021. Sixty-two patients received ruxolitinib-based therapy, whereas 102 received other systemic agents. In agreement with prospective trials, ruxolitinib resulted in a higher day 28 (D28) overall response Frate than nonruxolitinib therapies (55% vs 31%, P = .003) and patients who received ruxolitinib had significantly lower nonrelapse mortality (NRM) than those who received nonruxolitinib therapies (point estimates at 2-year: 35% vs 61%, P = .002). Biomarker analyses demonstrated that the benefit from ruxolitinib was observed only in patients with low MAGIC algorithm probabilities (MAPs) at the start of second-line treatment. Among patients with a low MAP, those who received ruxolitinib experienced significantly lower NRM than those who received nonruxolitinib therapies (point estimates at 2-year: 12% vs 41%, P = .016). However, patients with high MAP experienced high NRM regardless of treatment with ruxolitinib or nonruxolitinib therapies (point estimates at 2-year: 67% vs 80%, P = .65). A landmark analysis demonstrated that the relationship between the D28 response and NRM largely depends on the MAP level at the initiation of second-line therapy. In conclusion, MAP measured at second-line systemic treatment for acute GVHD predicts treatment response and NRM. The outcomes of patients with high MAP are poor regardless of treatment choice, and ruxolitinib appears to primarily benefit patients with low MAP.
Glycolysis in hepatic stellate cells coordinates fibrogenic extracellular vesicle release spatially to amplify liver fibrosis
Khanal, Shalil , Liu, Yuanhang , Wixom, Alexander Q. , Washington, Alexander M. , Jalan‐Sakrikar, Nidhi , Cooper, Shawna A. , Vučković, Ivan , Zhang, Song , Zhong, Jun , Johnson, Kenneth L. , Charlesworth, M. Cristine , Kim, I.Y. , Yeon, Yubin, Yoon, Sangwoong , Noh, Yung‐Kyun , Meroueh, Chady , Timbilla, Abdul Aziz , Yaqoob, Usman , Gao, Jinhang , Kim, Yohan , Hay, Nissim , Shah, Vijay H. , Bamidele, Adebowale O , Wixom, Alexander Q , Washington, Alexander M , Sakrikar, Nidhi Jalan , Cooper, Shawna A , Vuckovic, Ivan , Zhang, Song , Zhong, Jun , Johnson, Kenneth , Kim, Iljung , Yeon, Yubin , Yoon, Sangwoong , Noh, Yung-Kyun , Meroueh, Chady , Timbilla, Abdul Aziz , Gao, Jinhang , Kim, Yo Han , Lucien, Fabrice , Simons, Michael , Shah, Vijay H , Kostallari, Enis , Liu, Yuanhang, Bamidele, Adebowale O. , Charlesworth, M. Cristine , Yaqoob, Usman , Lucien, Fabrice , Huebert, Robert C. , Simons, Michael , Kostallari, Enis

Mayo Clinic

Science Advances | June 28, 2024 | Volume: 10 | Issue: 26 | Pages: No page available

10.1126/sciadv.adn5228 | PMID 38941469 Get It

Liver fibrosis is characterized by the activation of perivascular hepatic stellate cells (HSCs), the release of fibrogenic nanosized extracellular vesicles (EVs), and increased HSC glycolysis. Nevertheless, how glycolysis in HSCs coordinates fibrosis amplification through tissue zone-specific pathways remains elusive. Here, we demonstrate that HSC-specific genetic inhibition of glycolysis reduced liver fibrosis. Moreover, spatial transcriptomics revealed a fibrosis-mediated up-regulation of EV-related pathways in the liver pericentral zone, which was abrogated by glycolysis genetic inhibition. Mechanistically, glycolysis in HSCs up-regulated the expression of EV-related genes such as Ras-related protein Rab-31 ( RAB31 ) by enhancing histone 3 lysine 9 acetylation on the promoter region, which increased EV release. Functionally, these glycolysis-dependent EVs increased fibrotic gene expression in recipient HSC. Furthermore, EVs derived from glycolysis-deficient mice abrogated liver fibrosis amplification in contrast to glycolysis-competent mouse EVs. In summary, glycolysis in HSCs amplifies liver fibrosis by promoting fibrogenic EV release in the hepatic pericentral zone, which represents a potential therapeutic target.
Proceedings of PRINCETON IV: PDE5 inhibitors and cardiac health symposium
Rosen, Raymond C., Miner, Martin , Ganz, Peter , Kim, Noel N. , Köhler, Tobias , Lue, Tom F. , McVary, Kevin T. , Mulhall, John P. , Parish, Sharon J. , Sadeghi‐Nejad, Hossein , Sadovsky, Richard, Sharlip, Ira D., Ganz, Peter , Burnett, Arthur L. “Bud” , Blaha, Michael Joseph , Goldstein, Irwin , Kloner, Robert A.

Mayo Clinic

Sexual Medicine Reviews | June 28, 2024 | Volume: 12 | Issue: 4 | Pages: 681-709

10.1093/sxmrev/qeae043 | PMID 38936840 Get It

AbstractIntroductionPrior consensus meetings have addressed the relationship between phosphodiesterase type 5 (PDE5) inhibition and cardiac health. Given significant accumulation of new data in the past decade, a fourth consensus conference on this topic was convened in Pasadena, California, on March 10 and 11, 2023.ObjectivesOur meeting aimed to update existing knowledge, assess current guidelines, and make recommendations for future research and practice in this area.MethodsAn expert panel reviewed existing research and clinical practice guidelines.ResultsKey findings and clinical recommendations are the following: First, erectile dysfunction (ED) is a risk marker and enhancer for cardiovascular (CV) disease. For men with ED and intermediate levels of CV risk, coronary artery calcium (CAC) computed tomography should be considered in addition to previous management algorithms. Second, sexual activity is generally safe for men with ED, although stress testing should still be considered for men with reduced exercise tolerance or ischemia. Third, the safety of PDE5 inhibitor use with concomitant medications was reviewed in depth, particularly concomitant use with nitrates or alpha-blockers. With rare exceptions, PDE5 inhibitors can be safely used in men being treated for hypertension, lower urinary tract symptoms and other common male disorders. Fourth, for men unresponsive to oral therapy or with absolute contraindications for PDE5 inhibitor administration, multiple treatment options can be selected. These were reviewed in depth with clinical recommendations. Fifth, evidence from retrospective studies points strongly toward cardioprotective effects of chronic PDE5-inhibitor use in men. Decreased rates of adverse cardiac outcomes in men taking PDE-5 inhibitors has been consistently reported from multiple studies. Sixth, recommendations were made regarding over-the-counter access and potential risks of dietary supplement adulteration. Seventh, although limited data exist in women, PDE5 inhibitors are generally safe and are being tested for use in multiple new indications.ConclusionStudies support the overall cardiovascular safety of the PDE5 inhibitors. New indications and applications were reviewed in depth.
International consensus on the management of large (≥20 mm) colorectal laterally spreading tumors: World Endoscopy Organization Delphi study
Rex, Douglas K. , Aihara, Hiroyuki , Bastiaansen, Barbara A.J. , Bechara, Robert , Bhatt, Amit , Bourke, Michael J. , Byeon, Jeong‐Sik , Chino, Akiko , Goldblum, John R. , Ho, Shiaw Hooi , Jung, Yunho , Kawachi, Hiroshi , Khashab, Mouen A., Khomvilai, Supakij , Messmann, Helmut , Mori, Yuichi, Nakanishi, Yukihiro , Ngamruengphong, Saowanee , Parra‐Blanco, Adolfo , Pinto, Rafael Castilho , Pioche, Mathieu , Pohl, Heiko , Rastogi, Amit , Repici, Alessandro , Sethi, Amrita , Suzuki, Noriko, Tanaka, Shinji , Vieth, Michael, Yokoi, Chizu , Saito, Yutaka , Renteln, Daniel von , Chino, Akiko , Chiu, Philip Wai Yan , Elkholy, Shaimaa , Kawachi, Hiroshi , Yamamoto, Hironori , Yang, Dong-Hoon , Saito, Yutaka , Bhatt, Amit , Bechara, Robert , Djinbachian, Roupen , Chiu, Han‐Mo , Fukami, Norio , Bhandari, Pradeep , Cardoso, Daniela, Dekker, Evelien , Draganov, Peter V. , Emura, Fabian , Haji, Amyn , Khashab, Mouen A. , Kim, Eun Ran , Maselli, Roberta , Moons, Leon M.G. , Pellisé, Maria , Singh, Rajvinder

Mayo Clinic

Digestive Endoscopy | June 27, 2024 | Volume: 36 | Issue: 11 | Pages: 1253-1268

10.1111/den.14826 | PMID 38934243 Get It

ObjectivesThere have been significant advances in the management of large (≥20 mm) laterally spreading tumors (LSTs) or nonpedunculated colorectal polyps; however, there is a lack of clear consensus on the management of these lesions with significant geographic variability especially between Eastern and Western paradigms. We aimed to provide an international consensus to better guide management and attempt to homogenize practices.MethodsTwo experts in interventional endoscopy spearheaded an evidence‐based Delphi study on behalf of the World Endoscopy Organization Colorectal Cancer Screening Committee. A steering committee comprising six members devised 51 statements, and 43 experts from 18 countries on six continents participated in a three‐round voting process. The Grading of Recommendations, Assessment, Development and Evaluations tool was used to assess evidence quality and recommendation strength. Consensus was defined as ≥80% agreement (strongly agree or agree) on a 5‐point Likert scale.ResultsForty‐two statements reached consensus after three rounds of voting. Recommendations included: three statements on training and competency; 10 statements on preresection evaluation, including optical diagnosis, classification, and staging of LSTs; 14 statements on endoscopic resection indications and technique, including statements on en bloc and piecemeal resection decision‐making; seven statements on postresection evaluation; and eight statements on postresection care.ConclusionsAn international expert consensus based on the current available evidence has been developed to guide the evaluation, resection, and follow‐up of LSTs. This may provide guiding principles for the global management of these lesions and standardize current practices.
Tumor-Immune Signatures of Treatment Resistance to Brentuximab Vedotin with Ipilimumab and/or Nivolumab in Hodgkin Lymphoma
Gonzalez‐Kozlova, Edgar , Huang, Hsin-Hui , Jagede, Opeyemi A. , Tuballes, Kevin , Valle, Diane M. Del , Kelly, Geoffrey , Patel, Manishkumar , Xie, Hui , Harris, Jocelyn , Argueta, Kimberly , Nie, Kai , Barcessat, Vanessa , Moravec, Radim , Ansell, Stephen M. , Yu, Joyce , Cerami, Ethan , Lindsay, James , Wistuba, Ignacio I. , Gnjatic, Sacha , Jegede, Opeyemi A. , Del Valle, Diane M , Altreuter, Jennifer , Duose, Dzifa Y , Kahl, Brad S , Ansell, Stephen M , Yu, Joyce , Cerami, Ethan , Lindsay, James R , Wistuba, Ignacio I , Kim-Schulze, Seunghee , Diefenbach, Catherine S , Gnjatic, Sacha , Kahl, Brad S. , Diefenbach, Catherine

Mayo Clinic

Cancer Research Communications | June 27, 2024 | Volume: 4 | Issue: 7 | Pages: 1726-1737

10.1158/2767-9764.crc-24-0252 | PMID 38934093 Get It

Abstract To investigate the cellular and molecular mechanisms associated with targeting CD30-expressing Hodgkin lymphoma (HL) and immune checkpoint modulation induced by combination therapies of CTLA4 and PD1, we leveraged Phase 1/2 multicenter open-label trial NCT01896999 that enrolled patients with refractory or relapsed HL (R/R HL). Using peripheral blood, we assessed soluble proteins, cell composition, T-cell clonality, and tumor antigen-specific antibodies in 54 patients enrolled in the phase 1 component of the trial. NCT01896999 reported high (>75%) overall objective response rates with brentuximab vedotin (BV) in combination with ipilimumab (I) and/or nivolumab (N) in patients with R/R HL. We observed a durable increase in soluble PD1 and plasmacytoid dendritic cells as well as decreases in plasma CCL17, ANGPT2, MMP12, IL13, and CXCL13 in N-containing regimens (BV + N and BV + I + N) compared with BV + I (P < 0.05). Nonresponders and patients with short progression-free survival showed elevated CXCL9, CXCL13, CD5, CCL17, adenosine–deaminase, and MUC16 at baseline or after one treatment cycle and a higher prevalence of NY-ESO-1-specific autoantibodies (P < 0.05). The results suggest a circulating tumor-immune-derived signature of BV ± I ± N treatment resistance that may be useful for patient stratification in combination checkpoint therapy. Significance: Identification of multi-omic immune markers from peripheral blood may help elucidate resistance mechanisms to checkpoint inhibitor and antibody–drug conjugate combinations with potential implications for treatment decisions in relapsed HL.
Global retrospective study comparing consolidation ALK tyrosine kinase inhibitors (TKI) to durvalumab (durva) or observation (obs) after chemoradiation (CRT) in unresectable locally-advanced ALK+ non-small cell lung cancer (NSCLC).
Jayakrishnan, Ritujith, Lin, Jessica Jiyeong, Shakya, Purnima, Dilling, Thomas J. , Grohé, Christian , Fitzgerald, Bailey G. , Adib, Elio , Neal, Joel W. , Whitaker, Ryan, Mañana, Ana I. Velazquez, Goldberg, Sarah B. , Nassar, Amin H. , Shepherd, Frances Alice , Lin, Jessica Jiyeong, Lin, Steven H. , Bar, Jair , Gupta, Shruti , Sankar, K. Nathan , Yu, Helena Alexandra , Naqash, Abdul Rafeh , Kim, So Yeon

Mayo Clinic

Journal of Clinical Oncology | June 26, 2024 | Volume: 42 | Issue: 16_suppl | Pages: 8013-8013

10.1200/jco.2024.42.16_suppl.8013 Get It

8013 Background: For patients (pts) with unresectable locally-advanced NSCLC, standard of care involves durva consolidation after concurrent CRT, although its benefit in ALK+ tumors is unclear. The ALINA trial demonstrated adjuvant efficacy of alectinib in resected ALK+ NSCLC, but the optimal consolidation strategy for unresectable locally-advanced ALK+ NSCLC remains elusive. Methods: This multi-institutional international retrospective analysis included pts with stage III unresectable ALK+ NSCLC who received an ALK TKI, durva, or obs alone after concurrent CRT between 2015-2022. Baseline characteristics of age, sex, smoking history, and PD-L1 status were collected. Clinical outcomes including real-world progression-free survival (rw-PFS), overall survival (OS), and treatment-related adverse events (trAE) as defined using CTCAE 5.0 were assessed, and multivariate cox regression models were performed. Results: Sixty-four pts across 16 institutions were included. The median age was 57 (IQR 49-66) and 61% were females. The majority had adenocarcinoma (97%) and had never smoked (58%). 15 received ALK TKI (10 alectinib, 3 crizotinib, 1 brigatinib, 1 lorlatinib), 30 received durva, and 19 received obs alone. There was no significant difference in stage of cancer (IIIA, B, or C) or PD-L1 status among groups. After adjusting for stage and age at CRT initiation, median rw-PFS was significantly longer for ALK TKI (rw-PFS not reached [NR], 95% CI 22.7-NR) vs durva (11.3 months (mo), 95% CI 9.2-18.5, p= 0.005, HR = 0.12) or obs (7.4 mo, 95% CI 3.4-12.5, p < 0.0001). Two (13%) pts progressed on ALK TKI. 25 pts (83%) progressed on durva leading to treatment with ALK TKI in 23, and 18 (95%) progressed while under obs leading to treatment with ALK TKI in 15. 3-year OS was 100% for ALK TKI vs 90.5% for durva vs 63.5% for obs. Median OS was NR (95% CI NR-NR) for both ALK TKI and durva vs 70.6 mo (24.9-NR) in the obs group ( p= 0.03 for both ALK TKI and durva compared to obs). Median duration of therapy was 24.7 mo with ALK TKI and 6.5 mo with durva. Grade ≥3 trAE occurred in 27%, 7%, 6% of pts treated with ALK TKI (1 fatigue, 1 diarrhea, 1 hyperbilirubinemia, 1 pneumonitis), durva (1 fatigue, 1 neutropenia), and obs (1 neutropenia) respectively. Treatment discontinuation due to toxicity occurred in 4 (27%) with ALK TKI and in 3 (10%) with durva. Conclusions: In this retrospective study of stage III ALK+ NSCLC, consolidation ALK TKI demonstrated clinically meaningful improvement in PFS and OS over durva and obs, while showing a slightly higher rate of trAE over dura and obs. Furthermore, we show a high rate of progression following CRT alone in ALK+ NSCLC. These findings underscore the need for prospective molecularly driven trials to determine the optimal consolidation therapy for unresectable ALK+ NSCLC.